Genetics & Breast Cancer
Advertisement
High CIG signature or high sTILs linked to better survival in stage I TNBC; findings support further prognostic evaluation.
Dr. Eva Blondeaux discusses RRSO timing and fertility in young BRCA+ women and the need for shared, personalized decisions.
Risk-reducing surgery improves survival in young BRCA1/2 carriers, study shows, guiding counseling for high-risk patients.
Predictive genomics guides breast cancer care, helping tailor chemo decisions based on tumor gene expression.
Dr. Sadie Dobrozsi discusses the importance of "pan-cancer" testing, especially as it pertains to breast cancer.
The most frequent changes detected were additional copies of chromosome 1q and losses of chromosomes 10q, 16q, and 22.
Heterozygosity in BRCA1 genes is not enough to prevent tumor proliferation, according to researchers out of Harvard.
Researchers designed a interpretable deep learning model for detecting BRCA pathogenic variants of breast cancer.
This could be a needed breakthrough for those predisposed to breast and ovarian cancer mutations.
BUB1 has potential prognostic value in therapy decision-making across breast cancer characterizations.
Dr. Sadie Dobrozsi spoke on the importance of genetic testing in breast cancer to better understand the disease.
Researchers identified immune system white blood cells that appear closely related to BC cells that are likely to spread.
Researchers have completed the most extensive mapping of healthy breast tissue cells to date.
Researchers used a global DNA methylation profile to estimate the microenvironment of inflammatory breast cancer.
While half of all carriers of inherited cancer pathogenic variants are men, not enough men undergo genetic testing.
Using the HER2DX genomic tool is feasible in a real-world setting of patients with early-stage HER2-positive breast cancer.
Real-world outcomes were comparable to clinical trials in breast cancers with BRCA mutations treated with PARP inhibitors.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.